To The Moon

$Grab Holdings(GRAB)$ 🚗 Grab — Inflection Analysis This is no longer a cash-burn story. Grab has crossed into structural profitability. The superapp model is now generating real earnings and free cash flow, with operating leverage kicking in across mobility, deliveries, ads, and lending. 📈 Inflection status: CONFIRMED POSITIVE Revenue, margins, and cash flow have all turned sustainably positive. Atomic evidence: • FY25 net profit $200M vs $158M loss (FY24) • Q4’25 GMV $6.1B, +21% YoY • FY25 adj. FCF $290M • Adj. EBITDA +60% YoY to $500M • Loan book doubled to $1.18B ⚠️ Bottleneck: Financial Services segment breakeven targeted for 2H26. 💰 Price-conditioned valuation: At **US$4.23 (11 Feb 2026)**, the market discounts 2028 EBITDA/FC

$Oscar Health, Inc.(OSCR)$ 🏥 Oscar Health — Inflection Analysis This is a completed operating turnaround trading like a policy casualty. Oscar has reached scale profitability as a tech-native ACA insurer, but the stock is being dominated by fear around the 2026 subsidy cliff rather than fundamentals. 📈 Inflection status: CONFIRMED POSITIVE → STABILIZING Annual momentum remains intact despite near-term policy noise. Atomic evidence: • FY25 revenue $11.47B, +28% YoY • First full year of net income + adj. EBITDA profitability (2024) • SG&A ratio improved ~520bps via fixed-cost leverage • Operating cash flow $1.02B achieved in 2024 • Risk adjustment payable $1.68B reflects industry-wide morbidity spike ⚠️ Bottleneck: APTC renewal un

$ISHARESHSTECH(03067)$ $Lion-OCBC Sec HSTECH S$(HST.SI)$ The iShares Hang Seng TECH ETF signals a critical breakdown, having lost the vital 200-day EMA support ($11.67) for the third time—effectively a "three strikes" bearish confirmation. Trading decisively below this long-term trend setter and trapped within a descending channel, momentum is firmly negative. With the 20/50 EMAs now acting as overhead resistance, the inability to reclaim $11.67 implies the major trend has reversed, risking a continued slide toward the channel floor near $10.00-$10.50. @Tiger_comments @TigerObserver

🧠 $Microsoft(MSFT)$ — Inflection Analysis The market is stuck on capex fear. The data says demand is already locked in. Microsoft’s AI-driven cloud engine has moved from speculation to backlog-backed execution, with monetization now visible in Azure growth and RPO expansion. 📈 Inflection status: CONFIRMED POSITIVE Revenue, margins, and cash flow continue to inflect upward. Atomic evidence: • Azure growth re-accelerated to ~40% (FY26 Q1) • Commercial RPO surged to $625B, +110% YoY • AI now contributes ~16pts to Azure growth (+400bps in 6 months) • OpenAI signed ~$250B incremental Azure consumption deal • Operating cash flow +56% vs FY23 ⚠️ Bottleneck: GPU capacity and datacenter power limit near-term fulfillment. 💰 Price-conditioned

$Intel(INTC)$ 🧠 Intel (INTC) — Inflection Analysis Intel’s existential risk is gone — but the stock is now running ahead of the fundamentals. Backed by government funding and strategic equity from NVIDIA & SoftBank, Intel has established a hard strategic floor. The market is now pricing in execution perfection. 📈 Inflection status: CONFIRMED POSITIVE (structural) Balance sheet stabilized, narrative reset to IDM 2.0. Atomic evidence: • ~$7B NVIDIA/SoftBank investment at ~$23 (Q3’25) • Gross margin trough passed: 34.8% vs 32.7% in 2024 • Impairments down to $950M from $3.3B • Inventory reserves +$878M tied to early 18A ramp • Share count +16% YoY → dilution drag ⚠️ Bottleneck: Intel 18A HVM yield and external foundry customer ramp

$Dassault Systemes SA(DASTY)$ 🛠️ Dassault Systèmes (DSY.PA) — Inflection Analysis This is a quiet transition story the market is still doubting. Dassault is shifting from license-led PLM to a subscription-first 3DEXPERIENCE model. Headline growth looks soft, but revenue quality and margins are improving underneath. 📊 Inflection status: STABILIZING → EARLY POSITIVE Qualitative improvement ahead of reported growth. Atomic evidence: • Subscription revenue +16% Q3’25 (vs +9% last year) • Recurring revenue mix 86% (+300 bps YoY) • Non-IFRS op margin 30.1% (+100 bps) • Industrial Innovation +9% Q3’25, accelerating • 3DEXPERIENCE Cloud +36% Q3’25 ⚠️ Bottleneck: Medidata -3% growth and auto OEM volume contraction delaying top-line inflecti

$Adobe(ADBE)$ 🎨 Adobe — Inflection Analysis The stock is pricing in an AI death spiral. The numbers say otherwise. Adobe has stabilized and is quietly improving, with cash flow, margins, and ARR all decoupling from the bearish AI-disruption narrative. 📊 Inflection status: STABILIZING → IMPROVING Fundamentals are turning while sentiment remains fearful. Atomic signals: • FY25 operating cash flow >$10B, +28% vs FY23 • ARR $25.2B, +11.5% YoY — growth intact • Document Cloud +18% YoY (AI Assistant uptake) • GAAP operating income +29% YoY • FY26 ARR growth guide >10% 💰 Valuation at price: • Price: $303 (14 Jan 2026) • ~17x FY26 GAAP EPS vs >30x historical • Heavy buybacks confirm internal conviction • RPO $22.5B supports cash

$ResMed(RMD)$ 😴 ResMed (RMD) — Inflection Hunter Snapshot The market still fears GLP-1 drugs will kill sleep apnea demand. The numbers say otherwise. ResMed is showing a **confirmed positive inflection**, driven by margin expansion and earnings leverage — not hype. 📈 Inflection status: CONFIRMED POSITIVE Margins and earnings are accelerating faster than revenue. Atomic evidence: • Revenue +9% YoY to $1.34B (Q1 FY26) • Net income +12% YoY to $348.5M → clear operating leverage • Gross margin expanded to 59.4% (+80bps YoY) • Core Sleep & Breathing revenue +10% YoY ($1.17B) • Dividend raised 13% YoY to $0.60 This directly contradicts the “terminal decline from GLP-1” narrative. 💰 Balance sheet strength: • Cash $1.38B vs debt $668M →

$Astera Labs, Inc.(ALAB)$ 🧩 Astera Labs (ALAB) — Inflection Analysis This is the moment many IPOs fail to reach. Astera Labs has crossed from “AI promise” into **real, GAAP-profitable execution** — and the inflection is now confirmed. ALAB sits at the center of hyperscaler AI clusters, supplying the **connectivity backbone** (retimers, switches, modules) that makes large-scale AI compute actually work. 📈 Inflection status: CONFIRMED POSITIVE Profitability, cash flow, and scale efficiency have all flipped. Atomic evidence: • Q3’25 revenue $230.6M, +104% YoY • GAAP net income $91.1M vs loss last year • Diluted EPS $0.50 vs $(0.05) • YTD operating cash flow $224M • Gross margin ~76% while scaling hardware • R&D intensity fell to 34%

$DexCom(DXCM)$ 🩺 DexCom (DXCM) — Inflection Analysis DexCom is emerging from its 2024 slowdown — and the growth engine is re-accelerating. After a digestion year marked by channel resets and litigation overhang, DexCom is now benefiting from faster product cycles and an expanded addressable market beyond insulin users. 📈 Inflection status: CONFIRMED POSITIVE Direction: Improving (confidence: medium–high) Atomic evidence: • Revenue re-accelerated to +21% YoY (Q3’25) vs +11% FY’24 • Stelo (OTC, non-insulin) launched Aug’24 → major TAM expansion • G7 15-day clearance (Apr’25) restores product parity • Gross margin stabilized and expanded in Q3’25 on volume leverage • 500k–600k net users added in FY’24 (pre-Stelo) This is no longer just a